CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性弥漫大 B 细胞淋巴瘤新策略的探索
英文原题：Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
查看英文原题
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大B细胞淋巴瘤（DLBCL）是一种侵袭性且生物学异质性显著的疾病。约40%的DLBCL患者会复发，或对一线化学免疫治疗无应答。近年来，多种新型治疗药物获批用于复发/难治性（R/R）DLBCL，包括抗CD19CAR-T 细胞疗法，以及polatuzumab和tafasitamab等单克隆抗体。尽管这些新疗法均具有较高疗效，仍有患者不应答或复发，构成尚未满足的临床需求。本综述介绍正在临床开发、用于治疗R/R DLBCL的有前景新疗法。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous disease. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first-line chemo immunotherapy. In recent years, there have been several new therapeutic agents approved for the treatment of relapsed/refractory (R/R) DLBCL.
These agents include anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) and monoclonal antibody therapies such as polatuzumab and tafasitamab. Nevertheless, despite the high efficacy of all these new therapies, there are still patients who do not respond or relapse, representing an unmet clinical need. This review describes new promising therapies that are in clinical development to treat R/R DLBCL.
论文信息
- 作者
- Gonzalez Barca E
- 单位
- Hematology Department, Catalan Institute of Oncology-IDIBELL, University of Barcelona, 08908 Barcelona, Spain.Spain
- 文献类型
- 综述
- 期刊
- Journal of clinical medicine2023 Nov 28
- 原文标识
- PubMed 38068428 · DOI 10.3390/jcm12237376
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →